Citigroup Inc Fibrogen Inc Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	SELL	$0.38 - $0.91 $3,572 - $8,554	-9,400 Reduced 7.14%	122,200 $108,000
Q3 2023 Nov 09, 2023	BUY	$0.79 - $2.83 $32,232 - $115,464	40,800 Added 44.93%	131,600 $113,000
Q2 2023 Aug 10, 2023	BUY	$2.49 - $20.59 $226,092 - $1.87 Million	90,800 New	90,800 $245,000
Q4 2022 Feb 09, 2023	SELL	$13.27 - $17.73 $763,025 - $1.02 Million	-57,500 Reduced 48.94%	60,000 $961,000
Q3 2022 Nov 10, 2022	BUY	$11.4 - $14.6 $342,000 - $438,000	30,000 Added 34.29%	117,500 $1.53 Million
Q2 2022 Aug 10, 2022	BUY	$7.94 - $12.96 $694,750 - $1.13 Million	87,500 New	87,500 $924,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.